Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
$840.50
$8.96(1.38%)
At close: 4:00 PM EST
$840.50
$8.96(1.38%)
Day’s Range― - ―
52-Week Range$510.06 - $934.62
Previous CloseN/A
Volume151.62K
Average Volume (3M)316.08K
Market Cap
$51.63B
Enterprise Value$49.60B
Total Cash (Recent Filing)$3.93B
Total Debt (Recent Filing)$43.15M
Price to Earnings (P/E)39.5
Beta0.24
Next Earnings
Feb 26, 2026EPS Estimate
5.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.18
Shares Outstanding61,883,408
10 Day Avg. Volume338,225
30 Day Avg. Volume316,077
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)6.70
Price to Sales (P/S)16.81
P/FCF Ratio-243.71
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue21.62
Enterprise Value/Gross Profit32.66
Enterprise Value/Ebitda77.43
Forecast
1Y Price Target
$1,039.80Price Target Upside23.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical CatalystsMultiple late-stage clinical trial readouts across autoimmune indications present independent opportunities to secure new approvals and meaningfully expand the drug's addressable market.
Commercial TractionStrong commercial uptake of the lead therapy, supported by favorable payer contracts and high physician confidence, supports continued revenue growth and market share expansion.
Financial StrengthAchievement of operating profitability and a strong balance sheet provides flexibility to fund further development, pursue business development opportunities, and sustain commercial operations.
Bears Say
Pricing And Seasonality RiskSeasonality in use of injectable therapies combined with net pricing pressures could temporarily flatten revenue growth and weigh on near-term sales momentum.
Program DiscontinuationDiscontinuation of the phase three program in thyroid eye disease following a futility analysis removes a potential indication and may dampen investor confidence in the pipeline's near-term upside.
Valuation And Estimate RiskStretched valuation and reductions in platform and sales estimates increase downside risk if upcoming clinical readouts fail to exceed high market expectations.
Argenx Se News
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $510.06 and its highest was $934.62 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $51.63B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Feb 26, 2026 which is in 25 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Oct 30, 2025. The company reported $5.18 earnings per share for the quarter, beating the consensus estimate of $4.488 by $0.692.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 5.9.
How many shares outstanding does Argenx Se have?
Argenx Se has 61,883,408 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $5.18 in its last earnings report, beating expectations of $4.488. Following the earnings report the stock price went down -0.196%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,039.80 (23.71% Upside)
$1,039.80 (23.71% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 116.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 13.4%
Last 30 Days ▲ 13.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.26%
12-Months-Change
Fundamentals
Return on Equity
24.75%
Trailing 12-Months
Asset Growth
49.60%
Trailing 12-Months
Company Description
Argenx Se
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
ARGX Company Deck
ARGX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and successful product launches, particularly the PFS, alongside significant pipeline progress. However, there were setbacks in certain pipeline developments and increased operating expenses. Despite this, the positives of revenue growth and successful commercial strategies outweigh the negatives.View all ARGX earnings summariesARGX Stock 12 Month Forecast
Average Price Target
$1,039.80
▲(23.71% Upside)
Technical Analysis
Ownership Overview
―
Insiders
15.24% Mutual Funds
0.05% Other Institutional Investors
83.56% Public Companies and Individual Investors